SCYNEXIS Inc to Discuss the Ibrexafungerp Data Presented at ECCMID 2019 - Conference Call Transcript
Good day, ladies and gentlemen. Welcome to the SCYNEXIS Ibrexafungerp ECCMID 2019 Clinical Data Presentations Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
At this time, I would now like to turn the call over to Dr. Marco Taglietti, President and Chief Executive Officer of SCYNEXIS.
Thank you, operator. Welcome, and thank you for joining us to discuss the exciting new clinical data surrounding our lead product candidate, ibrexafungerp, that is being presented during the 29th European Congress of Clinical Microbiology Infectious Diseases or ECCMID in Amsterdam.
Let me remind you that during this call, we will be making forward-looking statements based on current expectations. Please refer to our SEC filings and detailed risk factors for further information. ECCMID is an important meeting for us given the exciting ibrexafungerp results. Across a total of 6 presentations, data we share that provide additional evidence of the potent
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |